vindesine - CISMeF

Preferred Label : vindesine;

MeSH definition : Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).;

MeSH synonym : vindesin; desacetylvinblastine amide;

CISMeF synonym : 59917-39-4 (Vindesine sulfate); EG labo brand of vindesine sulfate; lilly brand of vindesine sulfate;

MeSH hyponym : NSC-245467; eldisine; Vindesine Sulfate; compound 112531; Enison; Sulfate, Vindesine; NSC 245467; NSC245467;

MeSH CAS label : vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-;

MeSH Related Number : vindesine sulfate; 53643-48-4 (Vindesine); 59917-39-4 (SO4); CPH2U7DNDY;

Registry Number MeSH : 53643-48-4;

Related CAS MeSH : CPH2U7DNDY (Vindesine sulfate);

Codes EINECS : 258-682-2;

Is substance : O;

UNII : RSA8KO39WH;

InChIKey : HHJUWIANJFBDHT-ZVTSDNJWSA-N;

Details

Origin ID

D014751;

UMLS CUI

C0042682;

ATC code(s)
- vindesine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- vindesine [Substance BNPC]
Pharmacological action(s)
- antineoplastic agents, phytogenic [MeSH Descriptor]
- tubulin modulators [MeSH Descriptor]
Record concept(s)
- NSC-245467 [MeSH concept]
- Vindesine Sulfate [MeSH concept]
- compound 112531 [MeSH concept]
- eldisine [MeSH concept]
- vindesine [MeSH concept]
Related MeSH Supplementary Concept(s)
- APEL protocol [MeSH Supplementary Concept]
- BELD protocol [MeSH Supplementary Concept]
- BEMP protocol 2 [MeSH Supplementary Concept]
- CAD protocol 1 [MeSH Supplementary Concept]
- CAD protocol 2 [MeSH Supplementary Concept]
- CAPE protocol [MeSH Supplementary Concept]
- CEVD protocol [MeSH Supplementary Concept]
- CVB protocol [MeSH Supplementary Concept]
- Cis-VACD protocol [MeSH Supplementary Concept]
- DAC protocol [MeSH Supplementary Concept]
- DECAV protocol [MeSH Supplementary Concept]
- DVP protocol [MeSH Supplementary Concept]
- EBAP protocol [MeSH Supplementary Concept]
- ELETOP protocol [MeSH Supplementary Concept]
- EPVP protocol [MeSH Supplementary Concept]
- EV protocol [MeSH Supplementary Concept]
- EVI protocol [MeSH Supplementary Concept]
- HELP protocol [MeSH Supplementary Concept]
- HR-2 protocol [MeSH Supplementary Concept]
- IVEP protocol [MeSH Supplementary Concept]
- LNH 84 protocol [MeSH Supplementary Concept]
- LNH 87 protocol [MeSH Supplementary Concept]
- LNH-80 regimen [MeSH Supplementary Concept]
- LNH87-2 protocol [MeSH Supplementary Concept]
- LSG15 regimen [MeSH Supplementary Concept]
- MB-triple V protocol [MeSH Supplementary Concept]
- MCNU-VMP protocol [MeSH Supplementary Concept]
- MICE regimen [MeSH Supplementary Concept]
- MOPPEBVCAD protocol [MeSH Supplementary Concept]
- MTV protocol [MeSH Supplementary Concept]
- MV protocol 2 [MeSH Supplementary Concept]
- MiPE protocol [MeSH Supplementary Concept]
- N-(4-azido-3-iodosalicyl)-N'-beta-aminoethylvindesine [MeSH Supplementary Concept]
- N-(4-azidobenzoyl)-N'-beta-aminoethylvindesine [MeSH Supplementary Concept]
- OPP-EBV-CAD regimen [MeSH Supplementary Concept]
- OS 87 protocol [MeSH Supplementary Concept]
- PCV regimen [MeSH Supplementary Concept]
- PECC protocol [MeSH Supplementary Concept]
- PEEC protocol [MeSH Supplementary Concept]
- PEEC-M protocol [MeSH Supplementary Concept]
- VAE protocol [MeSH Supplementary Concept]
- VCH protocol [MeSH Supplementary Concept]
- VCPC protocol [MeSH Supplementary Concept]
- VDA-P protocol [MeSH Supplementary Concept]
- VEMP protocol 3 [MeSH Supplementary Concept]
- VEP protocol [MeSH Supplementary Concept]
- VINAP protocol [MeSH Supplementary Concept]
- VIP protocol 3 [MeSH Supplementary Concept]
- VMMc protocol [MeSH Supplementary Concept]
- VPIV protocol [MeSH Supplementary Concept]
- VQEP protocol [MeSH Supplementary Concept]
- VinMCP protocol [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing vindesine (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing vindesine (medicinal product) [SNOMED CT concept]
- Vindesine [ICD-11 Extension code]
- Vindesine [NCIt concept]
- Vindesine (substance) [SNOMED CT concept]
- vindesine [ATC Code]
- vindesine [Substance BNPC]
Validated automatic mappings to BTNT
- Vindesine Sulfate [NCIt concept]
- Vindesine sulfate [SMS substance]
- Vindesine sulfate (substance) [SNOMED CT concept]
- vincaleukoblastine, 3-(aminocarbonyl)-o4-deacetyl-3-de(methoxycarbonyl)-, sulfate (1:1) (salt) [Substance BNPC]
- vindesine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients